Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Search

Top

CONE BIOPRODUCTS OF SEGUIN, LLC

UEI: M1HTKQFCVA73

CONE BIOPRODUCTS OF SEGUIN, LLC is a federal contractor, registered under UEI M1HTKQFCVA73. It has been awarded $284,425 across 3 federal contracts. Primary work spans Biological Product (except Diagnostic) Manufacturing and In-Vitro Diagnostic Substance Manufacturing. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

M1HTKQFCVA73

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Department Of Health And Human Services$284.4K100%

Awards by NAICS

325414 - Biological Product (except Diagnostic) Manufacturing$276.4K97.2%

325413 - In-Vitro Diagnostic Substance Manufacturing$8.0K2.8%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in CONE BIOPRODUCTS OF SEGUIN, LLC's top NAICS codes and agencies

CONTROL, RESPIRATORY PA

Solicitation # SPE2DS-26-T-311F

The BioFire RP2.1/RP2.1plus Control Panel is a synthetic nucleic acid-based quality control product consisting of 12 vials, each containing 300 microliters of a non-infectious buffer solution with stabilizers and preservatives. It is designed for in vitro use with the FilmArray instrument to monitor the detection and identification of respiratory pathogens during RP2.1 panel testing. Each kit provides sufficient reagent for six quality control runs, including six positive and six negative controls. The product requires strict frozenstorage between -25°C and -15°C (-13°F to 5°F) and has a non-extendable shelf life of 18 months, with no more than two months allowed to have passed from the date of manufacture to delivery to the government. Labeling must include the date of manufacture, expiration date, contract number, and lot number in compliance with Medical Marking Standard No. 1, which supersedes MIL-STD-129. Packaging must meet commercial standards, ensuring protection against damage, with exterior containers suitable for safe transport at the lowest cost to the specified delivery point. The item is governed by DLA technical and packaging requirements, including RS013 for shelf life, RP001 for packaging standards, and RD003 for potential covered defense information. The National Stock Number is 6550-01-690-4435, with a procurement quantity of three kits under solicitation SPE2DS-26-T-311F, with a delivery deadline of 83 days after award.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

about 6 hours ago

DEADLINE

TEST KIT, BACTERIA D

Solicitation # SPE2DS-26-T-310W

The contract is for the procurement of 25 units of the API 20 E test kit, designed for the identification of Enterobacteriaceae and other gram-negative rods, under the NSN 6550-01-507-3726. Each purchase group (PG) equals 25 units, and the full order consists of exactly one PG. The product must be delivered within five days of contract award, with delivery terms specified as FOB destination, and no quantity variance is permitted. Strict shelf-life requirements apply: no more than three months may have elapsed from the date of manufacture to the date of delivery, and the item has a non-extendable shelf life of 18 months, classified as a TYPE I CODE K item. The test kits require refrigerated storage between 2 and 8 degrees Celsius at all times. Packaging must comply with commercial standards and Medical Marking Standard No. 1, superseding MIL-STD-129, with each unit sealed in protective containers and shipped in suitable exterior packaging to ensure safe delivery at the lowest freight rate. The product is regulated by the FDA, and the contracting official must submit a referral via EBS for confirmation, including manufacturer and part number details. The manufacturer is bioMérieux Inc with part number 20100. Technical and quality requirements are governed by the DLA Master List, and packaging, marking, and information security controls, including potential covered defense information, are mandated per applicable DLA directives. All documentation and compliance must align with the solicitation SPE2DS-26-T-310W, issued under NAICS code 325414 by the Department of Defense.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

about 6 hours ago

DEADLINE

TEST KIT, CORONAVIRUS D

Solicitation # SPE2DS-26-T-308W

The contract is for the procurement of 150,000 units of the QuickVue At-Home OTC COVID-19 Test kit, a rapid antigen detection system designed for self-administration using an anterior nasal swab. Each kit contains all necessary components for two tests, including a tube holder, two prefilled extraction tubes, two swabs, and two test strips with a dipstick format that delivers results in ten minutes through a two-color readout: a blue control line and a red test line. The test is intended for single-user administration, with the two tests in each kit to be performed 24 to 36 hours apart, eliminating the need for additional equipment or laboratory support. Built-in procedural controls ensure test validity, and all materials are pre-assembled for immediate use. The kits are to be delivered within 20 days of award under solicitation SPE2DS-26-T-308W, issued by the Department of Defense’s Medical Supply Chain MD Surg FSF, with performance specified to occur in West Los Angeles, CA. The contract includes adherence to DLA technical and quality requirements under RA001, packaging standards per RP001, and removal protocols for government identification on non-accepted items per RQ011, with the NSN 6550-01-697-6662 identifying the product for federal acquisition purposes.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

CONTROL SET, GLUCOSE

Solicitation # SPE2DS-26-T-308J

The control set for glucose is designed for use with the Accu-Chek Inform II system and includes two 2.5 mL vials—one each of Level 1 and Level 2 control solutions—to ensure accurate calibration and performance verification of test strips. It must be stored between 39 and 86 degrees Fahrenheit (4 to 30 degrees Celsius) and must not be frozen. The item is issued as a single unit and is subject to strict medical procurement standards, including commercial packaging requirements that ensure protection from damage and safe delivery by common carriers. All units must be marked in accordance with Medical Marking Standard No. 1, which supersedes MIL-STD-129, and include the date of manufacture, expiration or retest date, contract number, and lot number. The item has a non-extendable shelf life of 24 months, and no more than three months may have elapsed from the date of manufacture to the date of government delivery. Technical and quality requirements referenced under R and I numbers are governed by the DLA Master List, with revision standards tied to solicitation or award dates depending on acquisition size. This item is classified as a Type I (Code M) medical supply, and all labeling, packaging, and marking must comply with the latest version of MMS1C. The NSN is 6550-01-642-5011, the solicitation number is SPE2DS-26-T-308J, and delivery is required within 20 days after order award to Fort Campbell, with the contract managed by the Department of Defense under the Medical Supply Chain.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

DDDPlus Software Licensing and SupportThe contract entails the provision of five individual Standard licenses for DDDPlus software, covering full delivery, installation, and compatibility testing to ensure seamless integration with existing systems. License administration will be maintained throughout a four-year term, including ongoing support and compliance management. The work is performance-based with the place of performance located in Silver Spring, Maryland, under a subcontract structure, and falls under the NAICS code 511210 for software publishing. The Department of Health and Human Services is the contracting organization, with a response deadline set for August 14, 2026, and the solicitation was posted on August 4, 2026. All activities must align with federal procurement standards and deliverables must meet technical and operational requirements specified in the agreement.

Department Of Health And Human Services

POSTED

DEADLINE

GastroPlus Software Licensing and SupportThe contract awards the supply and ongoing support of 20 Standard licenses for GastroPlus software over a four-year period, encompassing full delivery, installation, and verification of compatibility with FDA systems. The provider is responsible for ensuring seamless integration into existing infrastructure and managing all aspects of license administration throughout the term. Performance is required to occur at the designated location in Silver Spring, Maryland, with the work falling under NAICS code 511210 for software publishing. The opportunity was posted on August 4, 2026, and responses are due by August 14, 2026, with the contracting entity being the Department of Health and Human Services. This subcontract supports critical regulatory and scientific operations that rely on GastroPlus for pharmacokinetic and pharmacodynamic modeling within federal health and safety contexts.

Department Of Health And Human Services

POSTED

DEADLINE

Custom Multi-Component Veterinary Drug Reference Standards (Sulfonamides)The contract involves the manufacture of two certified lots of multi-component sulfonamide reference standards for veterinary drug applications, each consisting of five 1mL ampules with precisely defined concentration ratios aligned to government-specified tables. The materials must be produced to meet stringent quality and stability requirements, including a minimum shelf life of 12 months at the time of shipment, ensuring long-term usability for regulatory and testing purposes. The standards are designated as ICV and CCV, indicating their use as independent calibration and control verification materials critical to analytical validation and compliance. The work is being procured by the FDA Office of Acquisition and Grant Services under the Department of Health and Human Services, with performance expected to occur in Denver, Colorado, and classified under NAICS code 325414 for pharmaceutical and botanical product manufacturing. Submission of proposals is due by August 7, 2026, and the contract is structured as a subcontract, suggesting it may follow an overarching government agreement. All output must adhere to exacting specifications to support federal laboratory and inspection protocols, with no flexibility permitted in composition, packaging, or stability validation.

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Custom Multi-Component Veterinary Drug Reference Standards (NSAIDs)The contract entails the manufacture and delivery of ISO 17034-certified analytical reference standards specifically for nonsteroidal anti-inflammatory drugs (NSAIDs) to support veterinary drug residue testing. Two certified lots—intermediate control verification (ICV) and candidate control verification (CCV)—will be produced, each containing five 1mL glass ampules sealed for stability and purity. The reference standards are to be dissolved in LC-MS grade solvents to ensure compatibility with high-performance liquid chromatography and mass spectrometry workflows. All materials must meet rigorous certification standards to guarantee accuracy, traceability, and consistency in quantitative analytical applications. The work is required to be completed under a subcontract with a response deadline of August 7, 2026, and the place of performance is designated as Denver, Colorado, with a zip code of 80225. The contracting entity is the FDA Office of Acquisition and Grant Services under the Department of Health and Human Services, operating under NAICS code 325414, which corresponds to pharmaceutical preparation manufacturing. The deliverables are critical for laboratory quality control and regulatory compliance in animal health testing, requiring strict adherence to certification protocols and documentation without compromising sample integrity or analytical validity.

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Fisher Scientific Reagents and Consumable Materials for Cell Therapy Manufacturing

Solicitation # 26-008155

The National Institutes of Health Clinical Center plans to award a sole-source firm-fixed-price purchase order to Fisher Scientific for validated reagents and consumable materials essential to the manufacturing of FDA-regulated cell-based therapies used in NIH clinical trials. These materials have been rigorously validated and approved by the Center for Cellular Engineering’s Quality Assurance Department to ensure consistent quality, safety, and efficacy in producing cell therapies for patient care. Any substitution of these materials would necessitate extensive and costly revalidation of manufacturing processes, leading to significant delays and potential risks to ongoing clinical trials, making Fisher Scientific the only viable supplier capable of providing the required validated products and supporting documentation compliant with federal regulatory standards. The acquisition is authorized under FAR 13.106-1(b)(1)(i), which allows for single-source procurement when only one provider can meet the government’s specific requirements, and the value does not exceed the simplified acquisition threshold. The product service code is 6550, and the NAICS code is 325413, classifying the items as in-vitro diagnostic substances. Performance will occur at the NIH Clinical Center in Bethesda, Maryland. While this notice does not solicit bids or proposals, responsible parties may submit capability statements by August 13, 2026, at 6:00 p.m. Eastern Time, referencing POTS 26-008155, though the government retains full discretion to proceed without competition. All inquiries should be directed to Shasheshe Goolsby of the Hospital and Laboratory Support Division.

National Institutes Of Health Olao

POSTED

DEADLINE

Intent to Sole Source - Endotoxin Detection System Cartridges

Solicitation # NOI-CC-OLAO-26-007979

The National Institute of Health, Clinical Center intends to sole source the purchase of proprietary endotoxin detection system cartridges from Charles River Laboratories to support the production and release of PET IND products. These cartridges are essential for bacterial endotoxin testing, ensuring all radiopharmaceuticals are pyrogen-free prior to patient administration, and are compatible only with the institution’s existing portable testing system. Due to the proprietary nature of the cartridges, no alternative suppliers can meet the technical requirements, justifying a sole source acquisition under 41 U.S.C. 253(c)(1) and FAR 6.302-1. The contract requires delivery of cartridges estimated at $22,200 by February 1, 2025, to prevent disruption in patient-ready product release; failure to meet this deadline would compromise the ability to conduct mandatory testing. A separate shipment for additional cartridges is also required by August 24, 2026, to sustain ongoing operations. This is not a request for proposal, but a notice of intent allowing other possible sources to submit capability statements by 12:00 PM Eastern Standard Time on August 7, 2026, to Valerie Gregorio at valerie.gregorio@nih.gov. All submissions received by the deadline will be evaluated, and the government retains full discretion to proceed without competition based on the responses.

National Institutes Of Health

POSTED

DEADLINE

Notice of Sole Source: GastroPlus PBPK and PBBM modeling platform subscription

Solicitation # 7571TE26Q00153

The U.S. Food and Drug Administration, through the Department of Health and Human Services, intends to sole-source a firm fixed-price contract to Simulations Plus Inc. for twenty GastroPlus and five DDDPlus software licenses, used for physiologically based pharmacokinetic and physiologically based biopharmaceutics modeling in support of generic drug research. The contract spans a base year from September 1, 2026, to August 31, 2027, with up to three one-year option periods extending through August 31, 2030. Performance will occur at the FDA’s White Oak campus in Silver Spring, Maryland. The acquisition is conducted under RFO 12, allowing for non-competitive procurement of commercial products, and no set-aside applies. Responses are due by August 14, 2026, and any interested party may submit a capability statement to demonstrate their ability to supply the exact software licenses as the original equipment manufacturer or authorized reseller, which the government will review solely to determine whether competitive procurement is warranted. The contract requires the vendor to provide standard individual licenses, with no auto-renewals permitted unless explicitly authorized. Acceptance of deliverables will be conducted by the Contracting Officer’s Representative within 30 working days of delivery, verifying software functionality, compatibility with FDA systems, and compliance with technical requirements. Invoicing must be submitted electronically through the Treasury’s Invoice Processing Platform, and all invoices must include detailed supporting documentation for labor, materials, and costs. The government retains the right to reject nonconforming deliveries and will not pay for services that fail to meet agreed standards. Clauses from the FAR and HHSAR govern payment, representation, whistleblower rights, anti-lobbying, accessibility, and dispute resolution, with federal regulations taking precedence over any vendor terms. The Contracting Officer and Contract Specialist are the primary points of contact, and all vendors must be actively registered in SAM at the time of submission.

Department Of Health And Human Services

POSTED

DEADLINE

CryoStor® CS10, 100 mL Bags for Cell Therapy Manufacturing

Solicitation # 26-007655

The National Institutes of Health Clinical Center plans to award a sole-source firm-fixed-price purchase order to BioLife Solutions for 80 bags of CryoStor® CS10, 100 mL, used exclusively for cryopreserving cell therapy products in FDA-regulated clinical trials. The product is essential to the Center for Cellular Engineering’s manufacturing processes, having been rigorously validated and approved by quality assurance to ensure the safety and consistency of therapies administered to patients. Substituting an alternative cryoprotectant would necessitate extensive revalidation, leading to significant delays, increased costs, and potential disruption to patient care. CryoStor® CS10 is the only commercial cryoprotectant with an FDA Master File and is the only product fully qualified for use in the NIH’s regulated environment, justifying the sole-source designation under FAR 13.106-1(b)(1)(i). The acquisition supports critical clinical research operations at the NIH Clinical Center in Bethesda, Maryland, under PSC 6550 and NAICS 325413. While the notice does not request formal proposals, responsible parties may submit capability statements by August 13, 2026, though the government reserves the right to proceed without competition. All submissions must reference solicitation number 26-007655 and be sent electronically to Shasheshe Goolsby at the NIH Office of Acquisitions and Logistics Management.

National Institutes Of Health Olao

POSTED

DEADLINE

Request for information - E60PH-28MPIV - Pandemic Influenza Vaccine Readiness and Supply Strategy

Solicitation # WS5703210526

Canada is seeking input from vaccine suppliers to inform its medium- and long-term strategy for ensuring readiness and supply of Pandemic Influenza Vaccine, with a target capacity to produce up to 110 million doses of a monovalent vaccine. This request for information aims to identify potential bidders capable of meeting the government’s needs for rapid, scalable vaccine production in the event of a pandemic, and to better understand industry capabilities, timelines, and conditions for fulfilling future contract opportunities. The initiative is led by the Department of Public Works and Government Services on behalf of the Government of Canada, with responses due by August 7, 2026, and all performance expected to take place within Canada. The NAICS code 325414 indicates the focus is on pharmaceutical and medicine manufacturing, and the sole point of contact for inquiries is Yessica Karnali Wijayaputri of SPAC/PSPC, reachable via email.

Department of Public Works and Government Services

POSTED

DEADLINE

CHIP, HYDROGEN PEROX

Solicitation # SPE2DS-26-T-300S

The contract under solicitation SPE2DS-26-T-300S is for the procurement of one unit of CHIP, HYDROGEN PEROXIDE for use with a CMS analyzer, featuring ten measurement capillaries filled with a substance-specific reagent detection system calibrated to a measuring range of 0.20–2.0 ppm and capable of conducting ten tests. The procurement is managed by the Defense Logistics Agency under the Department of Defense, with a response deadline of August 10, 2026, and a posted date of August 3, 2026. Delivery is required at Camp Carroll, Waegwan, Korea, under FOB Destination terms, with the item to be delivered within 84 calendar days of the request issue date, resulting in an anticipated delivery window ending around October 27, 2026. The contract specifies a fixed-price structure with no option quantities indicated, and while individual unit pricing is listed at $122.00, the total contract value cannot be determined due to incomplete pricing details. Compliance with stringent packaging and marking standards is mandatory, governed by MIL-STD-2073-1E and the Medical Marking Standard No. 1, which supersedes MIL-STD-129 for medical items. Labels must include the date of manufacture, expiration or retest date, contract number, and lot number, with hazardous material labeling adhering to the Hazard Communication Standard and specific submission requirements for hazard warning labels and material safety data sheets prior to award. The contractor must use Wide Area WorkFlow for electronic invoicing and receiving reports, and the government conducts all inspection and acceptance at the delivery point. Numerous FAR and DFARS clauses are incorporated, including those on employment eligibility verification, combating human trafficking, sustainable products, safeguarding contractor information systems, and NIST SP 800-171 compliance, some with deviations allowing for modified application. Offerors must hold a valid Unique Entity ID and CAGE code, submit socioeconomic status representations, and disclose any covered defense telecommunications equipment or joint venture partnerships. All proposals must be submitted electronically via DIBBS, and no physical attachments or formal evaluation factors are specified beyond implicit Low Price Technically Acceptable considerations typical of simplified acquisitions.

Defense Logistics Agency

POSTED

DEADLINE

QuantiFERON®-TB Gold Plus Reagent SupplyThe contract involves the supply of FDA-approved QuantiFERON-TB Gold Plus reagents designed for tuberculosis detection using the DiaSorin LIAISON XL instrument. This subcontract is issued by the Department of Veterans Affairs through the 257-NETWORK Contract Office 17, with performance required in Dallas, Texas, at ZIP code 75216. The reagents must meet stringent regulatory standards and be compatible with the specified diagnostic platform to ensure accurate and reliable results in clinical settings. The solicitation was posted on August 3, 2026, and responses are due by August 10, 2026, at 3:00 PM local time. The NAICS code 325414 identifies this as a business involved in the manufacturing of in vitro diagnostic substances. All reagents must be approved by the FDA and certified for use in tuberculosis screening programs within VA healthcare facilities.

257-NETWORK Contract Office 17 (36C257)

POSTED

DEADLINE

Unable to Decompose Subcontract OpportunitiesDue to a system error, the prime contract details necessary to identify or structure subcontract opportunities could not be retrieved, rendering all subcontracting analysis unavailable at this time. The solicitation is designated as a subcontract under the Department of Health and Human Services, with a posted date of August 3, 2026, and a response deadline of August 18, 2026. The place of performance is listed as Bethesda, Maryland, with a zip code of 20892, though no specific office address, point of contact, or set-aside information is provided. The NAICS code is marked as NA, and the agency and organizational designations are identical, indicating an internal system limitation. Despite the absence of actionable data for suppliers, the opportunity remains live in the system with a public view link available for reference.

Department Of Health And Human Services

POSTED

DEADLINE

Supply of Multi-Level Quality Controls – TRICONTROL

Great Plains Area Indian Health Svc

POSTED

DEADLINE

Reagent Supply – i-STAT CHEM8 Cartridges

Great Plains Area Indian Health Svc

POSTED

DEADLINE